Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Published byKory Ray Modified over 5 years ago

Similar presentations

Presentation on theme: "P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and."— Presentation transcript:

1 P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in the diabetes population, comparing P2Y12 blockade versus placebo in addition to aspirin. P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in the diabetes population, comparing P2Y12 blockade versus placebo in addition to aspirin. Jennifer A Rossington et al. Open Heart 2016;3:e000296 ©2016 by British Cardiovascular Society

Download ppt "P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and."

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430.

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
Randomized, double-blind, multicenter, controlled trial.

Randomized, double-blind, multicenter, controlled trial.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:306-313.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
LEADER trial: Primary Outcome

LEADER trial: Primary Outcome
Pravastatin in Elderly Individuals at Risk of Vascular Disease

Pravastatin in Elderly Individuals at Risk of Vascular Disease
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
TNT: Baseline and final LDL cholesterol levels

TNT: Baseline and final LDL cholesterol levels
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.

ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage.
on behalf of the LEADER Trial Steering Committee and Investigators

on behalf of the LEADER Trial Steering Committee and Investigators
Baseline characteristics of patients

Baseline characteristics of patients
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Relative risk of major events with atenolol vs placebo

Relative risk of major events with atenolol vs placebo
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Similar presentations

Ads by Google